Cheilonda Johnson

2.3k total citations
28 papers, 1.1k citations indexed

About

Cheilonda Johnson is a scholar working on Epidemiology, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cheilonda Johnson has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 15 papers in Rheumatology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cheilonda Johnson's work include Inflammatory Myopathies and Dermatomyositis (19 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Eosinophilic Disorders and Syndromes (12 papers). Cheilonda Johnson is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (19 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Eosinophilic Disorders and Syndromes (12 papers). Cheilonda Johnson collaborates with scholars based in United States, United Kingdom and Canada. Cheilonda Johnson's co-authors include Sonye K. Danoff, Lisa Christopher‐Stine, Andrew L. Mammen, Julie J. Paik, Jemima Albayda, Iago Pinal‐Fernandez, María Casal-Domínguez, J.A. Huapaya, Leann Silhan and Livia Casciola‐Rosen and has published in prestigious journals such as PLoS ONE, Neurology and CHEST Journal.

In The Last Decade

Cheilonda Johnson

27 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheilonda Johnson United States 17 779 494 429 210 138 28 1.1k
Yuji Hosono Japan 16 972 1.2× 700 1.4× 446 1.0× 151 0.7× 175 1.3× 36 1.1k
Roser Soláns-Laqué Spain 18 324 0.4× 412 0.8× 499 1.2× 223 1.1× 117 0.8× 52 1.1k
Yves Troyanov Canada 13 669 0.9× 345 0.7× 154 0.4× 213 1.0× 188 1.4× 24 864
Diane Koontz United States 14 990 1.3× 505 1.0× 173 0.4× 181 0.9× 162 1.2× 18 1.1k
Takahisa Gono Japan 18 412 0.5× 386 0.8× 219 0.5× 90 0.4× 86 0.6× 64 927
Aude Rigolet France 15 453 0.6× 283 0.6× 106 0.2× 110 0.5× 70 0.5× 44 738
Maurício Levy‐Neto Brazil 15 255 0.3× 309 0.6× 268 0.6× 109 0.5× 65 0.5× 43 671
Alisa N. Femia United States 15 260 0.3× 282 0.6× 149 0.3× 163 0.8× 195 1.4× 61 650
Harsha Gunawardena United Kingdom 21 1.6k 2.1× 1.1k 2.2× 201 0.5× 261 1.2× 290 2.1× 51 1.9k

Countries citing papers authored by Cheilonda Johnson

Since Specialization
Citations

This map shows the geographic impact of Cheilonda Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheilonda Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheilonda Johnson more than expected).

Fields of papers citing papers by Cheilonda Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheilonda Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheilonda Johnson. The network helps show where Cheilonda Johnson may publish in the future.

Co-authorship network of co-authors of Cheilonda Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Cheilonda Johnson. A scholar is included among the top collaborators of Cheilonda Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheilonda Johnson. Cheilonda Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anekwe, Chika V., Antonio Rico Cano, Seng Bin Ang, et al.. (2025). The role of lifestyle medicine in menopausal health: a review of non-pharmacologic interventions. Climacteric. 28(5). 478–496. 2 indexed citations
2.
Aggarwal, Rohit, Siamak Moghadam‐Kia, Sangmee Bae, et al.. (2025). Abatacept for the treatment of myositis-associated interstitial lung disease. Lara D. Veeken. 64(SI). SI156–SI168. 2 indexed citations
3.
Johnson, Cheilonda, Soroosh Solhjoo, W. Li, et al.. (2024). 099 Single-cell RNA sequencing reveals differential gene expression of cancer-associated fibroblast markers in mycosis fungoides by stage and race. Journal of Investigative Dermatology. 144(8). S18–S18.
4.
Aggarwal, Rohit, Siamak Moghadam‐Kia, Didem Saygın, et al.. (2023). POS1240 EFFICACY AND SAFETY OF ABATACEPT IN MYOSITIS ASSOCIATED INTERSTITIAL LUNG DISEASE. Annals of the Rheumatic Diseases. 82. 959–959. 2 indexed citations
5.
Dhanaliwala, Ali H., Scott Simpson, Drew A. Torigian, et al.. (2021). A CT Algorithm Can Elevate the Differential Diagnosis of Interstitial Lung Disease by Non-specialists to Equal That of Specialist Thoracic Radiologists. Academic Radiology. 29. S181–S190. 3 indexed citations
6.
Natalini, Jake G., Joshua F. Baker, Namrata Singh, et al.. (2020). Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans. Annals of the American Thoracic Society. 18(4). 598–605. 40 indexed citations
7.
Pinal‐Fernandez, Iago, Kevin J. Psoter, Julie J. Paik, et al.. (2019). The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Respiratory Medicine. 150. 63–65. 15 indexed citations
8.
Huapaya, J.A., Robert W. Hallowell, Leann Silhan, et al.. (2019). Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease. Respiratory Medicine. 154. 6–11. 34 indexed citations
9.
Huapaya, J.A., Leann Silhan, Iago Pinal‐Fernandez, et al.. (2019). Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. CHEST Journal. 156(5). 896–906. 73 indexed citations
10.
Casal-Domínguez, María, Iago Pinal‐Fernandez, Andrea M. Corse, et al.. (2019). Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology. 92(13). e1416–e1426. 38 indexed citations
11.
Pinal‐Fernandez, Iago, Christopher A. Mecoli, María Casal-Domínguez, et al.. (2019). More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology. 93(19). e1768–e1777. 34 indexed citations
12.
Johnson, Cheilonda, Paul C. Rosen, Thomas E. Lloyd, et al.. (2017). Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respiratory Medicine. 130. 52–54. 24 indexed citations
13.
Cox, Jacob T., David Gullotti, Christopher A. Mecoli, et al.. (2017). “Hiker’s feet”: a novel cutaneous finding in the inflammatory myopathies. Clinical Rheumatology. 36(7). 1683–1686. 37 indexed citations
14.
Johnson, Cheilonda. (2017). Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Current Opinion in Rheumatology. 29(3). 254–259. 49 indexed citations
15.
Albayda, Jemima, Iago Pinal‐Fernandez, Wilson Huang, et al.. (2017). Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care & Research. 69(11). 1771–1776. 117 indexed citations
16.
Johnson, Cheilonda, Jon T. Giles, Joan M. Bathon, et al.. (2016). Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis. PLoS ONE. 11(4). e0153024–e0153024. 18 indexed citations
17.
Johnson, Cheilonda, Iago Pinal‐Fernandez, Julie J. Paik, et al.. (2016). Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Lung. 194(5). 733–737. 96 indexed citations
18.
Johnson, Cheilonda, J. Lindsay Oaks, SeungHye Han, et al.. (2014). Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respiratory Medicine. 108(10). 1542–1548. 43 indexed citations
19.
Giles, Jon T., Erika Darrah, Sonye K. Danoff, et al.. (2014). Association of Cross-Reactive Antibodies Targeting Peptidyl-Arginine Deiminase 3 and 4 with Rheumatoid Arthritis-Associated Interstitial Lung Disease. PLoS ONE. 9(6). e98794–e98794. 63 indexed citations
20.
Thompson, A.M., et al.. (2002). Risk factors for post-stem cell transplant sinusitis. Bone Marrow Transplantation. 29(3). 257–261. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuji Hosono Breakdown of academic impact, for papers by Roser Soláns-Laqué Breakdown of academic impact, for papers by Yves Troyanov Breakdown of academic impact, for papers by Diane Koontz Breakdown of academic impact, for papers by Takahisa Gono Breakdown of academic impact, for papers by Aude Rigolet Breakdown of academic impact, for papers by Maurício Levy‐Neto Breakdown of academic impact, for papers by Alisa N. Femia Breakdown of academic impact, for papers by Harsha Gunawardena
Rankless by CCL
2026